Event-Driven Stocks

Keros Therapeutics, Inc.

KROSNasdaq

Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 7 gooddetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$244.1M$3.5M$151,000$0$20.1M$0
Operating income$67.6M−$210.8M−$169.9M−$114.8M−$56.4M−$46.7M
Net income$87.0M−$187.4M−$153.0M−$104.7M−$58.7M−$45.4M
Total assets$338.0M$615.9M$370.0M$306.8M$255.3M$269.4M
Total liabilities$34.9M$44.3M$37.8M$29.4M$12.1M$7.7M
Equity$303.1M$571.6M$332.2M$277.4M$243.2M$261.7M
EPS (diluted)$2.30$-5.00$-5.20$-4.15$-2.52$-2.93
Shares out.40.6M36.0M28.5M24.0M23.3M23.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
27.7%
Net margin
35.7%
Return on equity
28.7%
Return on assets
25.7%
Return on capital (ROCE)
21.3%
Liabilities / assets
10.3%
Debt / equity
0.12×
Book value / share
$7.47
Revenue growth (YoY)
6775.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
11.55safe
Accruals / assets
−6.1%clean
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
93
/ 100
Profitability 100Growth 100Catalyst 67Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 7 good
  • Operating margin is positive
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.7M4.7+20.4%
Apr 30, 20261.4M5.4+1.2%
Apr 15, 20261.4M3.5-6.4%
Mar 31, 20261.5M2.6-24.9%
Mar 13, 20262.0M3.5-2.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.